Skip Ribbon Commands
Skip to main content

DBBS

:

Events : Advancing the development of Nociceptin Opioid Receptor-targeted ligands as therapeutics for Substance use disorders

Export Event

Requestor

Amber Spies

Requestor Department

Anesthesiology

Requestor Phone

6187797827

Requestor Email

spiesa@wustl.edu

Type of Event

Scientific Seminar

Type of Lecture

Seminar Series

Start Time

9/27/2022 4:00 PM

End Time

9/27/2022 5:00 PM

Recurrence

 

All Day Event

 

Sponsoring Department/Group

Anesthesiology Research Seminar Series

Speaker/Honorific

Nurulain T. Zaveria, PhD

Speaker Affiliation

President and Chief Scientific Officer
Astraea Therapeutics, LLC

Title

Advancing the development of Nociceptin Opioid Receptor-targeted ligands as therapeutics for Substance use disorders

Add More Speakers (Optional)

No

2nd Speaker/Honorific

 

2nd Speaker Affiliation

 

2nd Title

 

3rd Speaker/Honorific

 

3rd Speaker Affiliation

 

3rd Title

 

4th Speaker/Honorific

 

4th Speaker Affiliation

 

4th Title

 

Location

Hybrid

Comments

EPNEC, Seminar Room A Zoom Meeting info: Please contact Amber Spies at spiesa@wustl.edu for details

Submit Another Request

No

Cancel Event

No

Career/Professional Development

No

PostdocEvent

No

Sponsor/Location

Anesthesiology Research Seminar Series -
Location:  Hybrid

Speaker/Title

Nurulain T. Zaveria, PhD -
Advancing the development of Nociceptin Opioid Receptor-targeted ligands as therapeutics for Substance use disorders

Sponsor/Speaker/Title/Location

Anesthesiology Research Seminar Series -
Location:  Hybrid -
Nurulain T. Zaveria, PhD -
Advancing the development of Nociceptin Opioid Receptor-targeted ligands as therapeutics for Substance use disorders

start

9/27/2022

ShowOnHomePage

No

Approved Event

Yes

iCal

http://dbbs.wustl.edu/_vti_bin/owssvr.dll?CS=109&Cmd=Display&List={3C2772E8-70D9-4EF9-BB74-B38E64DFF302}&CacheControl=1&ID=&Using=event.ics

Attachments

Content Type: Event
Created at 9/19/2022 1:56 PM by  
Last modified at 9/19/2022 3:15 PM by Andrew Richards